Thalidomide analogues: Derivatives of an orphan drug with diverse biological activity

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 2, 2004, Pages 215-229

  Luzzio, Frederick A ^a   Figg, William D ^b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cachexia; Chemotherapy; Glutarimide; HIV; Immunomodulatory; Metabolic activation; Multiple myeloma; Myelodysplastic syndrome; Phthalimide; Prodrug; Teratogenicity; TNF

Indexed keywords

2 (2,6 DIOXO 3 PIPERIDINYL)PHTHALIMIDINE; 3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; 5' HYDROXYTHALIDOMIDE; ANGIOGENESIS INHIBITOR; CC 3052; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GAMMA INTERFERON; GLUTARIMIDE DERIVATIVE; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; MITOXANTRONE; N PHTHALOYLGLUTAMIC ACID ANHYDRIDE; PHOSPHODIESTERASE IV INHIBITOR; PHTHALIMIDE DERIVATIVE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APHTHOUS ULCER; BEHCET DISEASE; CELL PROLIFERATION; CONSTIPATION; DEOXYGENATION; DROWSINESS; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG PENETRATION; DRUG STRUCTURE; EMBRYOTOXICITY; EOSINOPHILIA; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOMODULATION; LEG EDEMA; LEPROSY; MULTIPLE MYELOMA; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SEDATION; SIDE EFFECT; SKIN PERMEABILITY; SOLID TUMOR; STEREOCHEMISTRY; STRUCTURE ANALYSIS; TERATOGENICITY;

EID: 1342326793     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.2.215     Document Type: Review

References (66)

1. SERVICE RF: Can thalidomide be rehabilitated? Science (1995) 269:1340.
2. RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide: emerging role in cancer medicine. Ann. Rev. Med. (2002) 53:629-657.
3. MARRIOTT JB, MULLER G, STIRLING D et al.: Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin. Biol. Ther. (2001) 1:675-682.
4. MARRIOTT JB, MULLER G, DALGLEISH AG: Thalidomide as an emerging immunotherapeutic agent. Immunol. Today (1999) 20:538-540.
5. RAJE N, ANDERSON K: Thalidomide - a revival story. N. Engl. J. Med. (1999) 341:1606-1609.
6. HALES BF: Thalidomide on a comeback trail. Nat. Med. (1999) 5:489-490.
7. FICKENTSCHER K, KIRFEL A, WILL G et al.: Stereochemical properties and teratogenic activity of some tetrahydrophthalimides. Mol. Pharmacol. (1977) 13:133-141.
8. HELM F, FRANKUS E, FRIDERICHS E et al.: Comparative teratological investigation of compounds structurally and pharmacologically related to thalidomide Arzneim. Forsch. (1981) 31:941-949.
9. SHESKIN J: Thalidomide in the treatment of the lepra reaction. Clin. Pharmacol. Ther. (1965) 6:303.
10. SHESKIN J: The treatment of the lepra reaction in lepromatous leprosy. Fifteen years experience with thalidomide. Int. J. Dermatol. (1980) 6:318-322.
11. SAMPAIO EP, SARNO EN, GALILY R et al.: Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes J. Exp. Med. (1991) 173:699-703.
12. MULLER GW, CORRAL LG, SHIRE MG et al.: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity J. Med. Chem. (1996) 39:3238-3240.
13. CORRAL LG, MULLER GW, MOREIRA AL et al.: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor-α inhibitory activity. Molecular. Med. (1996) 2:506-515.
14. D'AMATO RJ, LOUGHNAN MS, FLYNN E et al.: Thalidomide is an inhibitor of angiogenesis. Proc. Natl Acad. Sci. USA (1994) 91:4082-4085.
15. REIST M, CARRUPT P-A, FRANCOTTE E et al.: Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem. Res. Toxicol. (1998) 11:1521-1528.
16. MULLER GW, KONNECKE WE, SMITH AM et al.: A concise two-step synthesis of thalidomide. Org. Proc. Res. Dev. (1999) 3:139-140.
17. SUZUKI E, SHIBATA N: Three-step synthesis of (R) and (S)-thalidomides from ornithine. Enantiomer (2001) 6:275-279.
18. ROBIN S, ZHU J, GALONS H et al.: A convenient asymmetric synthesis of thalidomide. Tetrahedron Asymmetry (1995) 6:1249-1252.
19. ISHIMURA K, HASHIMOTO Y, IWASAKI S: The (S)-form of α-methyl-N-(α)-phthalimidoglutarimide, but not its (R)-form, enhanced phorbol ester-induced tumor necrosis factor-α production by human leukemia cell HL-60: implication of optical resolution of thalidomidal effects. Chem. Pharm. Bull. (1994) 42:1157-1159.
20. LUZZIO FA, MAYOROV AV, FIGG WD: Thalidomide metabolites. Part 1: derivatives of (+)-2-(N-phthalimido)-γ-hydroxyglutamic acid. Tetrahedron Lett. (2000) 41:2275-2278.
21. LUZZIO FA, THOMAS EM, FIGG WD: Thalidomide metabolites and analogues. Part 2: cyclic derivatives of 2-N-phthalimido-2S, 3S(3-hydroxy) ornithine. Tetrahedron Lett. (2000) 41:7151-7155.
22. LUZZIO FA, ZACHERL DP, FIGG WD A facile scheme for phthalimide-phthalimidine conversion. Tetrahedron Lett. (1999) 40:2087-2090.
23. LUZZIO FA, MAYOROV AV, NG SSW et al.: Thalidomide metabolites and analogues. Part 3. Synthesis and antiangiogenic activity of the teratogenic and TNF-α-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine. J. Med. Chem. (2003) 46:3793-3799.
24. KNOCHE B, BLASCHKE G: Stereoselectivity of the in vitro metabolism of thalidomide. Chirality (1994) 6:221-224.
25. ERICSSON T, BJORKMAN S, ROTH B et al.: Hydroxylated metabolites of thalidomide: formation in vitro and in vivo in man. J. Pharm. Pharmacol. (1998) 50:1409-1416.
26. CZEJKA MJ, KOCH HP: Determination of thalidomide and its major metabolites by high performance liquid chromatography. J. Chromatog. (1987) 413:181-187.
27. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature (1993) 362:841-844.
28. FOLKMAN J: Tumor angiogenesis: a possible control point in tumor growth Ann. Intern. Med. (1975) 82:96-100.
29. TEUBERT U, ZWINGENBERGER K, WNENDT S et al.: 5¢-Substituted thalidomide analogs as modulators of TNF-α. Arkiv. Pharmazie (1998) 331:7-12.
30. NG SS, GUTSCHOW M, WEISS M et al.: Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res. (2003) 63:3189-3194.
31. NICOSIA RF, OTTINETTI A: A growth of microvessels in serum-free matrix culture of rat aorta. Lab. Invest. (1990) 63:115-122.
32. BAUER KS, DIXON SC, FIGG WD: Inhibition of angiogenesis by thalidomide requires metabolic activation which is species-dependent. Biochem. Pharmacol. (1998) 55:1827-1834.
33. MULLER GW, CHEN R, HUANG S-Y et al.: Amino-substitutedthalidomide analogs: potent inhibitors of TNF-α production. Bioorg. Med. Chem. Lett. (1999) 9:1625-1630.
34. DREDGE K, MARRIOTT JB, MACDONALD CD et al.: Novel thalidomide analogues display antiangiogenic activity independently of immunomodulatory effects. Br. J. Cancer (2002) 87:1155-1172.
35. DREDGE K, DALGLEISH AG, MARRIOTT JB: Thalidomide analogs as emerging anticancer drugs. Anti-Cancer Drugs (2003) 14:331-335.
36. MAKONKAWKEYOON S, LIMSON-PROBRE RNR, MOREIRA AL et al.: Thalidomide inhibits the replication of human immunodeficiency virus Type 1. Proc. Natl Acad. Sci. USA (1993) 90:5974-5978.
37. AGLE LMA, ROSENKRANZ M, LEHMAN TJA: Novel therapies for the treatment of juvenile rheumatoid arthritis (juvenile idiopathic arthritis). Expert Opin. Investig. Drugs (2003) 12:19-28.
38. VOGELSANG GB, FARMER ER, HESS AD et al.: Thalidomide for the treatment of chronic graft-versus-host disease. N. Engl. J. Med. (1992) 326:1055-1058.
39. TEO SK, CHEN Y, MULLER GW et al.: Chiral inversion of the second generation IMiD CC-4047 (ACTIMID) in human plasma and phosphate-buffered saline. Chirality (2003) 15:348-351.
40. LA MAESTRA L, ZANINONI A, MARRIOTT JB et al.: The thalidomide analogue CC-3052 inhibits HIV and tumor necrosis factor-alpha (TNF-α) expression in acutely and chronically infected cells in vitro. Clin. Exp. Immunol. (2000) 119:123-129.
41. MARRIOTT JB, WESTBY M, COOKSON S et al.: CC-3052: a water-soluble analogue of thalidomide and potent inhibitor of activation-induced TNF-α production. J. Immunol. (1998) 161:4236-4243.
42. ZHU X, GIORDANO T, YU Q-S et al.: Thiothalidomides: novel isosteric analogues of thalidomide with enhanced TNF-α activity. J. Med. Chem. (2003) 46:5222-5229.
43. + subset. J. Exp. Med. (1998) 187:1885-1892.
44. 3H] thymidine-dependence on the primary stimulant. Int. Immunopharm. (2002) 2:1143-1153.
45. + T cells. Clin. Exp. Immunol. (2002) 130:75-84.
46. BEKKER L-G, HASLETT P, MAARTENS G et al.: Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus Type I and tuberculosis. J. Infect. Dis. (2000) 181:954-965.
47. GORI A, ROSSI MC, TRABATTONI D et al.: Tumor necrosis factor-α increased production during thalidomide treatment in patients with tuberculosis and human immunodeficiency virus co-infection. J. Infect. Dis. (2000) 182:639-640.
48. WOLKENSTEIN P, LATARJET J, ROUJEAU J-C et al.: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet (1998) 352:1-4.
49. JACOBSON JM, GREENSPAN JS, SPRITZLER J et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N. Engl. J. Med. (1997) 336:1487-1493.
50. SCHAFER PH, GANDI AK, LOVELAND MA et al.: Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharm. Exp. Ther. (2003) 305:1222-1232.
51. H1-type immunity. J. Immunol. (2002) 168:4914-4918.
52. NOGUCHI T, SHIMAZAWA R, NAGASAWA K et al.: Thalidomide and its analogues as cyclooxygenase inhibitors Bioorg. Med. Chem. Lett. (2002) 12:1043-1046.
53. FUJITA J, MESTRE JR, ZELDIS JB et al.: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin. Cancer Res. (2001) 7:3349-3355.
54. ERIKSSON T, BJORKMAN S, HOGLUND P: Clinical pharmacology of thalidomide. Eur. J. Clin. Pharmacol. (2001) 57:365-376.
55. RICHARDSON P, HIDESHIMA T, ANDERSON K: Thalidomide in multiple myeloma. Biomed. Phamacother. (2002) 56:115-128.
56. SCHEY S, JONES R, RAJ K et al.: A Phase I study of an immunomodulatory drug (CC-4047), a structural analogue of thalidomide in relapsed/refractory multiple myeloma. Exp. Hematol. (2002) 30(Suppl.):248.
57. MARRIOTT JB, CLARKE IA, DREDGE K et al.: Thalidomide analogue CC-5013 is safe and well tolerated by patients with end-stage cancer and shows evidence of clinical responses and extensive immune activation. Br. J. Cancer (2002) 86(Suppl.):S26.
58. HIDESHIMA T, CHAUAN D, SHIMA Y et al.: Thalidomide and its analogues overcome drug resistance of multiple myeloma cells to conventional therapy. Blood (2000) 96:2943-2950.
59. LENTZSH S, ROGERS M, LEBLANC R et al.: 3-Amino-phthal-imido-glutarimide (S-3APG) inhibits angiogenesis and growth in drug resistant multiple myeloma in vivo. Blood (2001) 98(Part 1):1976.
60. MESSORI A, TRIPPOLI S, SANTARLASCI B: Pharmacotherapy of multiple myeloma: an economic perspective. Expert Opin. Pharmacother. (2003) 4:515-524.
61. SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple melanoma. N. Engl. J. Med. (1999) 341:1565-1571.
62. RICHARDSON PG, SCHLOSSMAN R, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063-3067.
63. LU J, PALMER BD, KESTELL P et al.: Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res. (2003) 9:1680-1688.
64. SORBERA LA, CASTANER J, BAYES M: CC-5013. Treatment of multiple myeloma, treatment of melanoma, treatment of myelodysplastic syndrome, angiogensis inhibitor, TNF-α production inhibitor. Drugs Fut. (2003) 28:425-431.
65. LIST AF, KURTIN SF, GLINSMANN-GIBSON BJ: High erythropoietic remitting activity of the immunomodulatory thalidomide analogue, CC-5013, in patients with myelodysplastic syndrome (MDS). Blood (2002) 100:(Part 1)353.
66. LIST AF, KURTIN S, GLINSMANN-GIGSON B: Efficacy and safety of CC-5013 for treatment of anemia in patients with myelodysplastic syndrome (MDS). Blood (2003) 102(Part1):641.